Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124

Key Points

• To assess the safety and efficacy outcomes of high-dose methotrexate across all age groups.
• Analysis of data from the HDMTX European Registry
• Review of treatment outcomes in various age groups
• Examination of adverse effects associated with high-dose methotrexate
• High-dose methotrexate shows favorable safety profiles in various ages
• Efficacy rates demonstrate effectiveness across treatment age spectrum
• Reported outcomes inform future high-dose methotrexate therapy strategies

Abstract